Connect with us

Cannabis News

Bipartisan Congressional Lawmakers Give Mixed Reactions To Marijuana Rescheduling News From Trump Administration

Published

7 months ago

on

Bipartisan congressional lawmakers are making a potentially immediate decision President Donald Trump to move forward with federal marijuana overhaul—Democrats like Rep. Alex Ocasio-Cortez (D-NY) call the reform a “no” and others like Rep. Andy Harris (R-MD) have pushed back against the proposal.

It was first reported on Thursday that Trump plans to sign an executive order on the reorganization, possibly directing the attorney general to complete the process started by the Biden administration to reclassify cannabis under Title III of the Controlled Substances Act (CSA).

Since then, several lawmakers from both sides of the aisle have weighed in on the plan in interviews with Marihuana Moment. While Democrats may disagree with the president on many policy issues, they have generally welcomed news of the restructuring’s development, though they would eventually like to see the federal ban end entirely rather than increase change.

Ocasio-Cortez said it was a “no brainer” to implement the policy change, which would legalize marijuana but remove some barriers to research and allow cannabis businesses to take a federal tax deduction, symbolically recognizing the plant’s medical value.

“I have honestly felt that it has been a race between the two major parties to get reform,” said the congressman. “I mean, it’s inevitable, so of course I’m all for that move.”

Asked about reports that House Speaker Mike Johnson (R-LA) told Trump not to reschedule, Ocasio-Cortez said an executive order would bypass lawmakers who oppose it. The speaker “has no pen” in such orders, he said.

“If he wants to try to pass some legislation and push his entire Republican team to do that, I think that’s within his power,” the congressman said.

Rep. Ilhan Omar (D-MN), co-chair of the Congressional Cannabis Caucus, told Marihuana Moment that while it’s true that Trump plans to advance rescheduling, that would be a “game changer” and a “huge” accomplishment.

However, he said that it is difficult for any member of parliament to take his word seriously, “because the president has often changed his position on various policy issues in the past. “I hope (he will act on the rescheduling) and it will come true,” he said.

Rep. Dina Titus (D-NV), another co-chair of the Congressional Cannabis Caucus, told Marijuana Moment that “Trump’s proposal would be a positive step toward cannabis policy reform, but more work remains.”

“While it would ease restrictions on medical cannabis research and alleviate some of the tax burden on state illegal cannabis businesses, classifying marijuana as a Schedule III substance still allows for the unfair and disproportionate incarceration of recreational users and limits access to banking services for cannabis businesses,” he said. “We must continue to address the systemic inequality associated with scheduling cannabis as a dangerous drug.”

House Majority Leader Steve Scalise (R-LA), for his part, did not weigh in on the merits of the reconsideration proposal, but told Marijuana Moment that he was with the president Thursday afternoon and “didn’t hear that” about plans to end the reform process.

One of the House’s most outspoken anti-marijuana lawmakers, Rep. Andy Harris (R-MD), insisted that he doesn’t “agree with everything the president does, and I don’t.” He also appears to question the veracity of recent reports about the imminence of a restructuring move, stating that he was told “for sure” it would happen on Thursday, which did not materialize.

There have been mixed reports on the timing of a possible reconsideration action, with some sources still hopeful it will happen on Friday, CNBC to report that the executive order would be issued on Monday of next week and as early as Axios to report that the reform is expected to come early next year.

Rep. Richard Hudson (R-NC), chairman of the National Republican Congressional Committee (NRCC), told Marihuana Moment that rescheduling is a “terrible idea” and noted that he had never discussed the issue with the House Speaker.

In a statement Friday, Sen. Kirsten Gillibrand (D-NY) said she was “encouraged to see the first move by the Drug Enforcement Administration under President Biden to reorganize marijuana, and I urge President Trump to continue that effort.”

“Common sense tells us that marijuana should not be in the same category as deadly drugs like heroin, and reclassifying it is a small step forward in creating economic opportunity, supporting research into the medical benefits of marijuana, and increasing public safety,” he said. “However, much more work remains to be done. I will continue to advocate for the complete decriminalization of marijuana and the expungement of the records of Americans convicted of marijuana possession.”

Rep. Ted Lieu (D-CA) reacted to the news by criticizing the Biden administration after it “failed” to complete marijuana rescheduling, and said he hopes the Trump administration doesn’t make the “same mistake.”

Meanwhile, Trump’s former White House press secretary, Sean Spicer, discussed the news development on an episode of his “The Huddle” podcast on Friday and said Trump’s potential reshuffle action, like other policy issues, “comes back to power and money.”

“There are a lot of people who instinctively think it’s a good play with young voters,” he said. “The bottom line, this whole reclassification, really comes down to the financial part of this.”

Spicer added that there is a “bank part” because cannabis companies have long faced a federal ban on accessing banking services, regardless of state laws. However, it inflated the impact of the reorganization on that issue, because placing marijuana in Schedule III of the CSA would not make it federally legal, so some banks would likely continue to avoid serving the marijuana industry even if this modest reform were enacted.

“It’s a big business with a lot of money, and I have to believe that’s what it really comes down to,” he said. “The president is not running for re-election … there are a lot of people who will not be happy about this. I am one of them.”




“You walk through downtown (Washington, DC) or any city, it smells like pot and piss,” he added. “I think, given where we are as a society, the last thing we need to do is make drugs more accessible. I don’t think it’s a good idea, but I’ll tell you, I think where people are missing the story is: Follow the money.”

Trump said this in mid-August he would make the reorganization decision in a week. But despite the growing timeline and rumors, a White House spokesperson told Marihuana Moments on Thursday that “no final decision has been made on rescheduling marijuana.”

The Washington Post reported Thursday afternoon that Trump planned to issue an executive order to federal agencies to move ahead with cannabis rescheduling.

The outlet also said the president met with marijuana industry executives Robert F. Kennedy Jr. earlier this week in the Oval Office. with Secretary of Health and Human Services and Centers for Medicare and Medicaid Services Administrator Mehmet Oz. During that meeting, Trump called Johnson, the House Speaker, who spoke out against the cannabis redistricting,

If the administration ultimately enacts the rescheduling, it would mark one of the most significant developments in federal marijuana policy since its prohibition half a century ago, when it was banned under Article III. With a reclassification, marijuana has medical value and a lower abuse potential compared to Schedule I drugs like heroin.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Trump endorsed the rescheduling — as well as an initiative to legalize access to industrial banking and adult use in Florida — on the campaign trail. The president had been silent on the issue since taking office for a second term, until a meeting in August where, in response to a reporter’s question, he announced that the administration would decide to reschedule in a few weeks.

The possibility of an immediate rescheduling announcement comes a few weeks later the president signed a major spending bill that would effectively ban most consumer hemp productsdrawing criticism from hemp industry players who say the policy change would wipe out the market.

LCB Contributed reporting from Washington DC

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Entourage Health, formerly WeedMD, enters creditor protection

Published

5 minutes ago

on

June 30, 2026

By

Entourage Health Corp. has entered creditor protection. The company and six related entities filed on June 17 under the Companies’ Creditors’ Arrangement Act owed approximately $240.1 million to the sole affiliate of the LiUNA Pension Fund, its owner, its secured creditor and the lender that is now funding the money (First Report pp. 3-6-9

That affiliate, 2437653 Ontario Inc. No. 1 company, Entourage, secured a 2024 deal that took the former WeedMD private and off the TSX Venture Exchange (December 2024 PR). Shareholders were paid half a Canadian cent per share, or C$0.005, and the board recommended a sale in December 2024 (December 2024 PR).

Jason Alexander, head of the special committee of independent directors, recommended to shareholders. “The transaction ensures that shareholders will receive immediate tangible value while positioning the Company for future growth and flexibility,” Alexander said (December 2024 PR). The company took on $167.6 million in debt in that sale, having already breached the covenant with the same guarantee (December 2024 PR). Eighteen months later that debt was $240.1 million when it was filed, and the growth promised by the sale is a settlement (First Report 6-18 p.

Adult use is off, medical is still running
The leisure business is closing, not saving. Entourage laid off about 53 workers in early June before the order, and 22 remain (First Report p. 6 Adult use inventory is being cleared, finished products are shipped to provincial distributors, and flowers are sold in bulk to the market to other licensed growers (First Report p. 12 Color Cannabis, Dime Bag and Saturday Cannabis are the brands going down with it (First Report p. 5

What remains open is the doctor’s arm as the exclusive supplier of cannabis under the Starseed brand to local residents of the Workers International Union of North America (First Report p. 5 The pension fund that funds the procedure is tied to the same union that the medical brand serves, and the part of Entourage that serves union members is the part that is kept alive while the rest is sold for parts.

At the end of July the money runs out with no new money (First Report p. 11 The money comes again from the pension fund affiliate, a $1.1 million debtor-in-possession facility at 5% per annum, no commitment fee, no exit fee (First Report pp. 10-11). The monitor, Ernst & Young, checked terms against other DIP loans in the cannabis sector from January 2024 and concluded that a third-party lender would not lend on better terms given the state of the business (First Report p. 11 The lender, which already owed $240 million, is the only one willing to advance another million to keep the lights on through the sale.

Health Canada is the largest unsecured creditor, owed $494,505, ahead of all suppliers and competitors on the company’s books (List of Creditors p. 1 Supreme Cannabis is owed $262,133, medical platform HelloMD is owed $169,564, the Town of Aylmer is owed $144,815, the Independent Retail Cannabis Board is owed $137,098 and High Tide is owed $124,583 (List of Creditors p. 1 Unsecured claims total $3,288,333 in more than 100 names, many of which have yet-to-be-determined amounts by medical clinics (List of Creditors 1-5 p. Against $240 million guaranteed, none of them will see much.

In the June 29 return, the lender asks the judge to extend the stay until August 28, approve the DIP facility, and double the Administrative and Directors fees to $500,000 each (First Report 4-8-12. p. The directorship is rising as directors face payroll, holiday pay and excise duties over a longer period of time, and the company’s directors and officers insurance expires at the start of July (First Report p. 12

The sales process starts on the same day, based on a marketing effort that started around May and was presented before the deal that sparked interest but no one could make a deal (First Report p. 13 Insiders and affiliates have until July 6th to say they intend to bid, the bid deadline is July 30th, the successful bid must be received by August 7th, and the outside deadline is August 28th (First Report p. 15 The affiliate of the pension fund has written to the Monitor that it will not make an offer (First Report p. 16), and any other affiliate that does so must be removed from the process (First Report p. 16 The settlement request for non-cannabis equipment and the sale of the Aylmer facility, a 26,000-square-foot extraction and processing facility that has been the company’s production base at 250 Elm St.

the source

For more information:
Neighborhood Health
1.844.933.3636
(email protected)
entouragehealthcorp.com

Continue Reading

Cannabis News

DEA And FDA Highlight How Marijuana Is Safer Than Alcohol And Opioids During Rescheduling Hearing’s Opening Day

Published

12 minutes ago

on

June 30, 2026

By

Attorneys for the Drug Enforcement Administration (DEA) on Monday highlighted testimony about the medical benefits of marijuana and its relative safety compared to other substances such as alcohol and opioids in the opening day of a hearing. The Trump administration’s cannabis rescheduling proposal.

Marijuana Moment spoke with several people in the audience for Monday’s hearing to find out how the testimony is going, despite the proceedings not being broadcast live to the public at the request of one congressman and others.

According to those sources, DEA attorney James J Schwartz stated that the government is the proponent of the proposed rule to formally move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), stating that the hearing is “not about the recreational use of marijuana” and “about regulation, not about legalization.”

“The government has presented no evidence to suggest that marijuana is not dangerous. All controlled substances are dangerous,
he said “However, controlled substances must be evaluated against the risks they pose, balanced against the medical benefits they provide.”

Dominic Chiapperino, director of the Food and Drug Administration’s Center for Controlled Drug Evaluation and Research and one of two DEA witnesses, testified about how federal health officials formed their recommendation to reschedule cannabis.

Opponents of the reform have used a new two-part test that they argue is a bad departure from a previous analysis, although a DEA lawyer said the hearing is not about that issue, and Chiapperino said the new test is now considered “every time” a new analysis is done on a drug.

The FDA official said the agency compared marijuana to alcohol, opioids and other substances in its scheduling analysis, and found that marijuana’s daily harms were lower than all or most of those comparators.

Cannabis is associated with fewer overdose deaths than comparable substances, Chiapperino said, and when reports of cases involving deaths mention marijuana, the deaths are often attributed to secondary incidents such as accidents or self-inflicted harm. Marijuana’s potential for overdose deaths is “much lower” than other Schedule I drugs and Schedule II drugs. Rather than opioids, the FDA official said.

As for withdrawal in regular users, Chiapperino testified that cannabis has symptoms similar to tobacco, including irritability, but alcohol has “more of a withdrawal syndrome,” which can include seizure and death.

Also on Monday, the lawyers of some of the parties against the reorganization had the opportunity to cross Chiapperino.

Kevin Sabet, president and CEO of the prohibitionist organization Smart Approaches to Marijuana, who was also invited to attend the hearing, said in a video posted on social media that it is “surreal” to see the government arguing that cannabis’s medical uses and relatively minor harms are “just lying through their teeth.”

The DEA “is in a very awkward position to argue the opposite of what it’s been arguing for the last 50 years, the opposite of what the science says, the opposite of what the evidence is,” he said, “which is, of course, to argue against the government that marijuana is more harmful than we thought, not less harmful.”

On Tuesday, opponents of the review will have an opportunity to cross-examine the FDA official, and the government’s second witness, Corey Burchman, a doctor from New Hampshire, will begin his testimony. The DEA announced in a filing last week that it will do so Testify on “How Medical Marijuana Provides Medical Benefit to Pain Patients.”

On Monday, a DEA attorney said Burchman would “describe the real-world impacts of treating pain with marijuana instead of opioids” based on his experience with both and discuss how he has “personally transitioned patients from opioids to marijuana for their pain.”

The witness will also testify about the differences between cannabis and opioids in terms of withdrawal and overdose, he said.

Before the hearing began, marijuana reform activists rallied They held a press conference outside DEA headquarters to highlight how they feel of the process – criticizing the fact that supporters of the reform were not invited to participate and that the proceedings are not reproduced live, despite the “transparency” oath of the officials.

DEA Administrator Terrance Cole only organizations and individuals opposed to marijuana reform have been invited to the hearing as a designated participant – telling followers that they do not meet the definition of “interested person” to participate because they are not “affected or prejudiced by any rule or proposed rule that may be issued.”

last week, Marihuana Moments sent petitions to DEA Chief Administrative Law Judge Derek Julius and DEA Administrator Cole asking for them reverse the decision to ban the public from tuning into the cannabis hearing via live stream. A Congressmen and other journalists later joined that request.

—
Marijuana Moment’s journalism is made possible by readers like you, who value this work enough to support us Patreon Monthly Pledges. If you rely on our reports to stay informed of important developments in cannabis, please help us do this becoming a permanent subscriber today.

Backed by us at the $25/month level, you’ll have access to our Bill Tracker so you don’t miss any important marijuana legislation in your state.
—

The opponents who are participating in the hearing submitted statements last week anticipate the anti-marijuana arguments they intend to make during the procedure.

The hearing it will end before July 15.

Acting Attorney General Todd Blanche in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA).

According to a separate order signed by the acting attorney general, the upcoming hearing will include Class III marijuana.

Preliminary hearing process on the marijuana redistricting process initiated by the Biden administration It was halted last year amid allegations of improper communications and witness selection.

the current The marijuana redistricting process is being challenged in several ways which have been upheld by a federal Court of Appeals. those pieces of State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.

Meanwhile, the reorganization of state-licensed medical cannabis is already having a major impact.

The Congressional Research Service published a report on the current rescheduling of cannabis Certified patients with medical marijuana from state licensed dispensaries are now eligible for Class III. “The order appears to allow end users to use marijuana medically without a CSA prescription,” he says.

The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has published a Draft update to a gun purchase form to recognize the legal status of medical marijuana in the reprogramming. The revised section of the question states that only the “recreational use or possession of marijuana” is federally prohibited, omitting the prior form’s mention of medical cannabis.

The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

Even the DEA, which has long opposed cannabis legalization and accused the Biden administration of stalling the initiative in the reorganization process, has done so. It launched a registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.

The Department of Transport, on the other hand, issued guidelines stating this use Legal medical cannabis in the state is still no excuse for truck drivers to test positive for drugspilots and other safety-sensitive personnel.

A congressional committee recently Federal officials voted to block further steps to reschedule cannabishowever lawmakers from both parties told Marihuana Moment they don’t think that provision will be enacted become law

user photo Carlos Gracia.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

cbdMD welcomes White House call for fair treatment of hemp-derived products

Published

1 day ago

on

June 29, 2026

By











cbdMD welcomes the Administration’s call for Congress to ensure fair treatment of hemp-derived products under federal law and calls for immediate action to revise hemp regulations to ensure fair treatment of hemp products under federal law.

In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority strongly supported by the Administration. The petition calls on Congress to ensure fair treatment of hemp-derived products by maintaining access to appropriate full-spectrum CBD products, and by maintaining Congress’ intent to reduce products that pose health risks. The administration also urged Congress to pass a responsible federal framework or at least extend the current implementation period to give lawmakers time to get policy right. The request builds on the president’s previous public statements urging lawmakers to protect access to full-spectrum CBD products that millions of Americans rely on.

“We are encouraged to see the administration so clearly championing the responsible, scientific hemp products that consumers depend on every day,” said Ronan Kennedy, CEO of cbdMD. “cbdMD has always believed that the future of this category is built on quality, transparency, and clear rules that separate them from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty to companies that provide certainty is what this industry and the people it serves deserve. We applaud the policymakers who are working to achieve this outcome.”

“We believe CbdMD is purpose-built for this next phase of the market,” added Kennedy. “Our focus remains on serving our customers with reliable and effective products, supporting responsible regulation and building long-term value for our shareholders as the category continues to evolve. Along the way, we will continue to evaluate the opportunities this evolving environment holds.”

For more information:
cbdMD
cbdmd.com/










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media